{"url_path":"/sec/jagx/8-k/2026-06-11/item-9-01","section_key":"item-9-01","section_title":"Item 9.01 Financial Statements and Exhibits.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-11","source_url":"https://www.sec.gov/Archives/edgar/data/1585608/0001193125-26-266770-index.html","accession_number":"0001193125-26-266770","cik":"0001585608","ticker":"JAGX","issuer_name":"Jaguar Health, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1585608/0001193125-26-266770-index.html","primary_entity_key":"0001585608","primary_entity_name":"Jaguar Health, Inc."},"word_count":164,"has_tables":true,"body_markdown":"Item 9.01\n\nFinancial Statements and Exhibits.\n\n(d) Exhibits\n\n \n\nExhibit\nNo.\n\n  \nDescription\n\n 3.1\n  \n[Certificate of Designation of Preferences, Rights and Limitations of Series P Non-Convertible Preferred Stock.](d570985dex31.htm)\n\n 4.1\n  \n[Form of the Commencement Pre-Funded Warrant.](d570985dex41.htm)\n\n10.1\n  \n[ELOC Agreement, dated June 9, 2026, by and between Jaguar Health, Inc. and the Institutional Investor named therein.](d570985dex101.htm)\n\n10.2\n  \n[ELOC Registration Rights Agreement, dated June 9, 2026, by and between Jaguar Health, Inc. and the Institutional Investor named therein.](d570985dex102.htm)\n\n10.3\n  \n[Form of the Preferred Stock Purchase Agreements.](d570985dex103.htm)\n\n10.4\n  \n[Preferred Registration Rights Agreement, dated June 9, 2026, by and between Jaguar Health, Inc. and the Investors named therein.](d570985dex104.htm)\n\n104\n  \nCover Page Interactive Data File (embedded within the inline XBRL document)\n\nSIGNATURES\n\nPursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.\n\n \n\n \n\n \n\n \nJAGUAR HEALTH, INC.\n\nDate: June 11, 2026\n \n\n \nBy:\n \n\n/s/ Lisa A. Conte\n\n \n\n \n\n \nLisa A. Conte\n\n \n\n \n\n \nChief Executive Officer & President"}